Protalix Biotherapeutics Inc. buy klostergang
Start price
08.04.15
/
50%
€18.27
Target price
08.10.15
€24.00
Performance (%)
-46.14%
End price
08.10.15
€9.84
Summary
This prediction ended on 08.10.15 with a price of €9.84. Massive losses of -46.14% were the result for the BUY prediction by klostergang. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Protalix Biotherapeutics Inc. | -0.713% | -0.713% | 58.333% | 54.472% |
| iShares Core DAX® | 0.855% | 0.389% | 2.533% | 52.003% |
| iShares Nasdaq 100 | -0.989% | -4.400% | 25.154% | 77.536% |
| iShares Nikkei 225® | -1.781% | -11.216% | 44.398% | 64.676% |
| iShares S&P 500 | 0.057% | 0.778% | 20.953% | 63.009% |
Comments by klostergang for this prediction
In the thread Protalix Biotherapeutics Inc. diskutieren
Protalix BioTherapeutics
Protalex recently received FDA clearance to begin a Phase 1/2 study with PRTX-100 in Immune Thrombocytopenia (ITP).
Previous data with PRTX-100 in patients with Rheumatoid Arthritis (RA) demonstrated the drug to be both safe and highly efficacious.
(Laufzeit überschritten)